CDKL5 Deficiency Disorder: Some Lessons Learned 20 Years After the First Description

Area of Science:

• Genetics and Molecular Biology
• Neuroscience
• Developmental Biology

Background:

• CDKL5 deficiency disorder (CDD) is caused by loss-of-function variants in the CDKL5 gene.
• Most CDD cases result from de novo missense or truncating variants.
• The CDKL5 gene was identified in 1998 during genomic mapping of the Xp22 region.

Purpose of the Study:

• To provide a comprehensive overview of CDKL5 deficiency disorder.
• To focus on the pathophysiology and clinical manifestations, particularly seizures.
• To outline current management guidelines and incorporate caregiver perspectives.

Main Methods:

• Review of existing literature on CDKL5 deficiency disorder.
• Analysis of clinical data and reported disease progression.
• Synthesis of information from scientific meetings and regulatory discussions.

Main Results:

• Significant progress has been made in understanding CDD pathophysiology since its initial human description in 2003.
• Seizures are a key clinical manifestation requiring focused attention.
• Established guidelines exist for disease management.

Conclusions:

• CDKL5 deficiency disorder requires a multidisciplinary approach to management.
• Continued research is vital for improving patient outcomes.
• Incorporating patient and caregiver experiences is crucial for comprehensive care.